Ilaris 150 MG/ML vialml
Ended Awarded Last action
- Contract number
- SPE2DR26FQWM4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $43,929
Award facts
- Contract value 100% obligated
- $43,929.03 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $43,929.03 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of ILARIS 150 mg/ml vials. The contract is firm fixed-price with no set-aside designation and is scheduled for completion by February 19, 2026. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded in November 2025 with a $499.999 billion ceiling value extending through December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the Department of Defense's global medical supply chain, leveraging its small business status to compete in federal procurement while maintaining demonstrated performance across multiple therapeutic categories. The PPV-G GEN V program represents the Defense Logistics Agency's $30.3 billion acquisition strategy to establish multiple regional prime vendor contractors capable of delivering comprehensive pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to military healthcare facilities worldwide. The company's product portfolio encompasses specialty pharmaceuticals, oncology treatments, immunosuppressants, vaccines, and emergency medications, positioning it as a key supplier for DoD healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FQWM4?
SPE2DR26FQWM4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FQWM4 worth?
The government has obligated $43,929 on SPE2DR26FQWM4.
Is contract SPE2DR26FQWM4 an order under another contract?
Yes. SPE2DR26FQWM4 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWM4 competed?
The extent of competition for SPE2DR26FQWM4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award